Last reviewed · How we verify
NCT07449910
Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial
Phase 2, PHASE3 trial testing 2mg Baricitinib in Acute Ichemic Stroke in 750 participants. Not yet recruiting.
17 August 2027
Quick facts
| Lead sponsor | The First Affiliated Hospital of University of Science and Technology of China |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 750 |
| Start date | 17 March 2026 |
| Primary completion | 17 August 2027 |
| Estimated completion | 31 January 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- 2mg Baricitinib — full drug profile →
- 4mg Baricitinib — full drug profile →
- Placebo
- Guideline-based therapy — full drug profile →
Conditions studied
- Acute Ichemic Stroke — all drugs for Acute Ichemic Stroke →
- Anterior Cerebral Artery Stroke — all drugs for Anterior Cerebral Artery Stroke →
- Baricitinib — all drugs for Baricitinib →
Sponsor
The First Affiliated Hospital of University of Science and Technology of China
Who can join
18 and older, any sex, with Acute Ichemic Stroke or Anterior Cerebral Artery Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary purpose of this study is to evaluate the efficacy and safety of Baricitinib combined with endovascular therapy in patients with acute anterior circulation large vessel occlusion, to address futile recanalization with priority, and to elucidating the mechanism of JAK/STAT pathway inhibition on neuroprotection and inflammatory regulation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07449910
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The First Affiliated Hospital of University of Science and Technology of China trials
Trials by the same sponsor.
- NCT07168278 — Tenecteplase vs Medical Management in 4.5-24h LVO no Access to EVT · Phase 3 · not yet recruiting
- NCT07214142 — Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer · Phase 2 · not yet recruiting
- NCT07094763 — Efficacy and Safety of Tenecteplase Intravenous Thrombolysis in Acute Posterior Circulation Ischemic Stroke Within 4.5-2 · NA · not yet recruiting
- NCT06559475 — A Multicenter, Randomized Controlled Clinical Investigation to Evaluate the Safety and Effectiveness of the Super-Bore 8 · NA · recruiting
- NCT06559436 — Extending the Time Window for Intravenous Tenecteplase in Patients With Distal Medium Vessel Occlusions Stroke · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07449910 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of University of Science and Technology of China
- Last refreshed: 4 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07449910.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing